Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
XN

NASDAQ · XNCR

Xencor, Inc.

Healthcare · Biotechnology

$27.80

Up+$0.80 (+2.96%)

Updated Aug 22, 2026, 3:31 AM

SID Score

6.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.22B
P/E ratio
-7.12
Dividend yield
0.00%
52-week range
$7.13 – $28.16
Volume
753.11K
Avg. volume
1.16M

Price performance

XNCR price history

1M range · 21 trading sessions · Daily adjusted prices

XNCR closed at $27.80 after 21 trading sessions, up 43.00% for the selected period.

Last close
$27.80
Period change
+43.00%
Period low
$19.40
Period high
$27.80
Daily close
View OHLC price history
XNCR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 21, 2026$27.30$28.16$27.07$27.80753.11K
Aug 20, 2026$27.01$27.70$26.52$27.001.66M
Aug 19, 2026$26.03$27.59$25.545$27.522.35M
Aug 18, 2026$22.81$25.53$22.79$25.411.6M
Aug 17, 2026$23.215$23.47$22.9119$23.12962.16K
Aug 14, 2026$22.91$23.45$22.50$23.34443.07K
Aug 13, 2026$23.36$23.40$22.53$22.99975.3K
Aug 12, 2026$22.13$23.34$21.895$23.181.97M
Aug 11, 2026$21.75$22.22$21.38$22.101.11M
Aug 10, 2026$20.915$21.81$20.48$21.581.26M
Aug 7, 2026$20.22$21.0514$19.925$20.811.12M
Aug 6, 2026$21.96$21.96$19.07$20.00996.66K
Aug 5, 2026$20.01$20.3299$19.65$19.84826.09K
Aug 4, 2026$19.69$20.26$19.49$19.92760.79K
Aug 3, 2026$20.07$20.24$19.09$19.40714.42K
Jul 31, 2026$21.50$21.57$19.77$20.211.32M
Jul 30, 2026$19.675$21.76$19.66$21.491.62M
Jul 29, 2026$19.93$20.12$19.20$19.531.16M
Jul 28, 2026$19.84$20.135$19.04$19.97845.86K
Jul 27, 2026$19.482$20.60$19.46$19.86942.3K
Jul 24, 2026$19.53$19.90$18.94$19.44632.99K

Latest XNCR news

The latest Smart Investors Daily articles mentioning XNCR.

Stock researchCompany · Overview

XNCR research

Overview

Company profile and research snapshot.

Company profile

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$27.60
Implied upside
—
Analysts
—
XNCR recent ratings
DateFirmRatingTarget
Aug 6, 2026Cantor FitzgeraldOverweight—
Aug 6, 2026WedbushOutperform—
Aug 6, 2026RBC CapitalOutperform—
Jul 30, 2026WedbushOutperform—
Jul 7, 2026Truist SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 8, 2026

How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit

Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.41. Over the first half of 2026, however, Xencor’s net loss widened to US$150.65 million and loss per share to US$1.99, highlighting a tension between short-term quarterly progress and heavier year-to-date spending. We’ll now consider how this quarterly...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By